Nevro (NVRO) Misses Q3 EPS by 57c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Nevro Reports Third Quarter 2021 Financial Results and Provides Fourth Quarter Guidance
November 8, 2021 4:05 PM ESTREDWOOD CITY, Calif., Nov. 8, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2021 and provided fourth quarter of 2021 guidance.
Third Quarter Updates, Recent Highlights and Guidance
Late July FDA Approval of 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) Third Quarter 2021 Worldwide Revenue of $93.2 Million; Decrease of 14% Compared to Prior Year and... More